%0 Journal Article %J The Journal of antimicrobial chemotherapy %D 2006 %T Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. %A Friedland, Gerald %A Khoo, Saye %A Jack, Christopher %A Lalloo, Umesh %K Adult %K Anti-HIV Agents %K Antibiotics, Antitubercular %K Benzoxazines %K CD4 Lymphocyte Count %K Chromatography, High Pressure Liquid %K Didanosine %K Drug Therapy, Combination %K Female %K HIV Infections %K Humans %K Lamivudine %K Longitudinal Studies %K Male %K Oxazines %K Rifampin %K Treatment Outcome %K Tuberculosis, Pulmonary %K Viral Load %N 6 %P 1299-302 %R 10.3109/00952990.2011.568081 %V 58 %X Pharmacokinetic interactions between rifampicin and antiretroviral therapy (ART), including efavirenz, are problematic and need to be better defined to determine proper dose and to be correlated with short-term and long-term clinical outcomes. %8 2006 Dec